Table of Contents

company-logo

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GlycoMimetics Dividend Announcement

• GlycoMimetics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on GlycoMimetics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

GlycoMimetics Dividend History

GlycoMimetics Dividend Yield

GlycoMimetics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing GlycoMimetics stock? Use our calculator to estimate your expected dividend yield:

GlycoMimetics Financial Ratios

P/E ratio-0.49
PEG ratio0.11
P/B ratio1.71
ROE-160.93%
Payout ratio0.00%
Current ratio0.00
Quick ratio0.00
Cash Ratio0.00

GlycoMimetics Dividend FAQ

Does GlycoMimetics stock pay dividends?
GlycoMimetics does not currently pay dividends to its shareholders.
Has GlycoMimetics ever paid a dividend?
No, GlycoMimetics has no a history of paying dividends to its shareholders. GlycoMimetics is not known for its dividend payments.
Why doesn't GlycoMimetics pay dividends?
There are several potential reasons why GlycoMimetics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will GlycoMimetics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While GlycoMimetics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is GlycoMimetics a dividend aristocrat?
GlycoMimetics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is GlycoMimetics a dividend king?
GlycoMimetics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is GlycoMimetics a dividend stock?
No, GlycoMimetics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy GlycoMimetics stocks?
To buy GlycoMimetics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy GlycoMimetics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.